 CAMBRIDGE, Mass. BEIJING--BUSINESS WIRE--- BGNE BTKi--BeiGene, Ltd. NASDAQ: BGNE; HKEX: 06160, a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Phase 2 trial evaluating BRUKINSA zanubrutinib in patients hospitalized with respiratory symptoms of COVID-19, requiring supplemental oxygen without mechanical ventilation, did not meet the co-primary efficacy endpoints of respiratory failure-free survival or reduction in days 